Guizhou Yibai Pharmaceutical Co Ltd (600594) - Total Liabilities
Based on the latest financial reports, Guizhou Yibai Pharmaceutical Co Ltd (600594) has total liabilities worth CN¥1.16 Billion CNY (≈ $169.24 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Guizhou Yibai Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Guizhou Yibai Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Guizhou Yibai Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Guizhou Yibai Pharmaceutical Co Ltd balance sheet assets.
Guizhou Yibai Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Yibai Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mobilicom Limited Warrants
NASDAQ:MOBBW
|
USA | $11.91 Million |
|
Geron Co Ltd
SHE:002722
|
China | CN¥690.51 Million |
|
Fibra Shop
MX:FSHOP13
|
Mexico | MX$13.14 Billion |
|
PRA Group Inc
NASDAQ:PRAA
|
USA | $4.02 Billion |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
USA | $1.71 Billion |
|
Chongqing Sansheng Building Materials Co Ltd
SHE:002742
|
China | CN¥895.14 Million |
|
Codere Online US Corp
NASDAQ:CDRO
|
USA | $50.38 Million |
|
NOUVEAU MONDE GRAPHITE
F:NM9A
|
Germany | €94.60 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Guizhou Yibai Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Guizhou Yibai Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Yibai Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Yibai Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.17 Billion ≈ $171.39 Million |
-21.58% |
| 2024-12-31 | CN¥1.49 Billion ≈ $218.56 Million |
-5.41% |
| 2023-12-31 | CN¥1.58 Billion ≈ $231.06 Million |
-5.78% |
| 2022-12-31 | CN¥1.68 Billion ≈ $245.23 Million |
+11.31% |
| 2021-12-31 | CN¥1.51 Billion ≈ $220.31 Million |
-14.61% |
| 2020-12-31 | CN¥1.76 Billion ≈ $258.02 Million |
-6.95% |
| 2019-12-31 | CN¥1.89 Billion ≈ $277.29 Million |
-26.12% |
| 2018-12-31 | CN¥2.56 Billion ≈ $375.34 Million |
+0.47% |
| 2017-12-31 | CN¥2.55 Billion ≈ $373.58 Million |
+6.54% |
| 2016-12-31 | CN¥2.40 Billion ≈ $350.64 Million |
+17.60% |
| 2015-12-31 | CN¥2.04 Billion ≈ $298.16 Million |
-1.63% |
| 2014-12-31 | CN¥2.07 Billion ≈ $303.10 Million |
+63.30% |
| 2013-12-31 | CN¥1.27 Billion ≈ $185.61 Million |
+73.44% |
| 2012-12-31 | CN¥731.33 Million ≈ $107.02 Million |
+9.89% |
| 2011-12-31 | CN¥665.51 Million ≈ $97.38 Million |
-3.38% |
| 2010-12-31 | CN¥688.82 Million ≈ $100.80 Million |
+20.58% |
| 2009-12-31 | CN¥571.26 Million ≈ $83.59 Million |
-7.95% |
| 2008-12-31 | CN¥620.62 Million ≈ $90.82 Million |
+1.70% |
| 2007-12-31 | CN¥610.24 Million ≈ $89.30 Million |
+8.53% |
| 2006-12-31 | CN¥562.27 Million ≈ $82.28 Million |
-13.85% |
| 2005-12-31 | CN¥652.65 Million ≈ $95.50 Million |
+80.74% |
| 2004-12-31 | CN¥361.10 Million ≈ $52.84 Million |
+31.35% |
| 2003-12-31 | CN¥274.93 Million ≈ $40.23 Million |
+57.22% |
| 2002-12-31 | CN¥174.87 Million ≈ $25.59 Million |
+29.36% |
| 2001-12-31 | CN¥135.18 Million ≈ $19.78 Million |
-- |
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells novel pharmaceutical products in China. The company offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, dripping pills, and oral solutions in the areas of tumor system, cerebrovascular and cardiovascular, respirato… Read more